 SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 GLOBE NEWSWIRE -- VistaGen Therapeutics NASDAQ: VTGN, a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system CNS disorders, today announced that management will participate in the Canaccord Genuity 41st Annual Growth Conference including a fireside chat with Shawn Singh, Chief Executive Officer, on Wednesday, August 11 at 1:30 p.m. PT. VistaGen will also be participating in one-on-one meetings throughout the conference. 